UK Community Advisory Board (UK-CAB)
Email | |
  • JOIN THE NETWORK

    • UK-CAB 4: Friday 31 January 2003

    31/01/2003 Alison Neathey
    Off
    Meetings

    Introduction to meeting and speakers
    Reading Material
    Agenda for the meeting
    Report from the meeting

    1. Introduction to meeting and speakers

    Dr Ranjababu Kulasegaram Guy’s & St Thomas’ Hospital

    HIV and hepatitis C co-infection

    Dr Ranjababu Kulasegaram (Babu) Dr Ranjababu Kulasegaram started specialising in GU/HIV medicine after his general medical training and has been working at Guy’s and St Thomas’ Hospital since 1995. His special interest is in managing patients with treatment difficulties, coinfection with hepatitis C and B and in patient care.

    Paul Bateman
    Living with multiple conditions

    Living outside London, having three medical conditions, visiting three departments in two hospitals and deciding whether to take hep C treatment!

    Robert James
    Personal experience of 48 weeks of interferon and ribavirin

    A year in the life of Rob, weekly interferon injections, coping with side-effects, complications with HIV medication, abstaining from alcohol. Was it worth it?

    2. Reading Material

    In preparation for the next CAB you will need to have internet access for about 30 minutes and preferably access to a printer, and about 30 minutes to look over the material.

    If you have any problems you can email Paul Foster or myself or you can call the office between 10-12am any morning next week and we’ll try to give give very limited IT support.

    3. Agenda for the meeting

    9.15 – 10.30 Women and HIV why gender is a real issue – feedback from two recent meetings in the US by Polly Clayden.
    10.30 – 11.00 Internal UK-CAB and feedback and Roche pre-meeting
    11.00 – 11.30 Break
    11.30 – 12.20 HIV and hepatitis c co-infection Dr Ranjababu Kulasegaram (Babu) Dr Ranjababu Kulasegaram started specialising in GU/HIV medicine after his general medical training and has been working at Guy’s and St Thomas’ Hospital since 1995. His special interest is in managing patients with treatment difficulties, coinfection with hepatitis C and B and in patient care.
    12.20 – 12.35 Living with multiple conditions Paul, Living outside London, having three medical conditions, visiting three departments in two hospitals and deciding whether to take hep C treatment!
    12.35 – 12.50 48 weeks of interferon and ribavirin Robert James A year in the life of Rob, weekly interferon injections, coping with side-effects, complications with HIV medication, abstaining from alcohol. Was it worth it?
    12.50 – 1.00 Questions for all three speakers
    1.00 – 2.00 Lunch
    2.00 – 3.30 Roche HCV department Dr Colin Hayward
    Proposed agenda
    1. introductions
    2. introduction to Roche approach to HCV products
    3. trials results, by genotype, time on treatment etc
    4. management of side effects
    5. pricing and access issues
    6. future developments (treatment and monitoring)

    Financial support

    The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year. This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering.

    The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

    We believe that manufacturers who currently develop and market medicines have a responsibility to actively engage with advocacy organisations and that HIV positive people and their advocates should be able to directly question manufacturers about the safety and efficacy of their products and proposals for future research.

    For a list of companies that support the UK-CAB please see the “about us” page.

    Meetings
    Meetings